Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SR 4554

Known as: SR-4554 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Nitroimidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
2-Nitroimidazole as Potential Nanoprobe in Hypoxia Imaging by MRI/PET
2-Nitroimidazole is radiosensitizer and serves as imaging contrast agent by 19Fand 31P MR methods. Despite the success of… Expand
  • table 1
  • figure 3
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
Review
2003
Review
2003
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
PURPOSE To perform a Phase I study of SR-4554, a fluorinated 2-nitroimidazole noninvasive probe of tumor hypoxia detected by (19… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Is this relevant?
2002
2002
Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
PURPOSE Tumor hypoxia is associated with poor prognosis and a more malignant tumor phenotype. SR-4554, a fluorinated 2… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
1998
1998
The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
The relationship between two methods of assessing tumour oxygenation in vivo, namely oxygen electrode measurement and magnetic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
1998
1998
Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo.
The purpose of this study was to examine the effect of carbogen gas (95% O2-5% CO2) on uptake and metabolism of 5-fluorouracil… Expand
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1997
1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
A novel probe, N-(2-hydroxy-3,3,3,-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554), has been used to detect tumor… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1997
1997
Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
The aim of this work was to study the metabolic characteristics of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2… Expand
Is this relevant?
1996
1996
The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
N-(2-Hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) is a fluorinated 2-nitroimidazole which has been… Expand
Is this relevant?
1995
1995
The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy…
The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and… Expand
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
Is this relevant?
1995
1995
Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma.
N-(2-Hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide, a novel 2-nitroimidazole, is currently being developed as… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE